Banjo, corrodes - Hl have of late manpower issues and cutting down on services like bed and isa, trading account openings to name a few .
However is it not just easy to SELL stocks from say Shares non-ISA account and buy same shares in next say 30minutes into an ISA account ( does not apply to funds as they take time) .
Only downside is trading charges . I have not done this before but considering . Have I simplified it too much ?
RK Beekeeper, Lewis bacon , Testing 321-
-I am a GGP holder and obviously very pleased with it. From the BB there i was suggested PRIM, and having researched looks very good and fits in well because
- good BOD
- investment in atleast 4 promising projects
- diversification
- relatively minimal risk.
- mutual fund type approach in starters
Have seen RKs assessment of SP on the light of GGPs success .
Would value any further pros and cons.
Have just recently thrown my hat in here as a tester. Ha Ha
Thanks
M Kumar
Gimmethe money- I know artemis site is beside GGPs Hv site
I am also with Interactive.
In summary what are the current prices and potential at Artemis and antipa as i considering this too given GGps potential
thank you
Hydro from your message below- i thought we were already on AIM 100 . did you mean we were added on to this list from now onwards. Does this then forms the basis for consideration towards Ftse 500 depending on the merits .
Hydro- Don't know @Mkumar. That's 'crystal ball' stuff isn't it. The learning, if there is one is that if you want to sell 12m, there's a buyer at very close to market price, so the stock is very bullish. It is gaining support at levels beyond most private investors. But I guess we suspect that already with Sprott. We're Aim 100 as of next week. And we've got news flow in-extremis. It's all good.
OlderWiser-
Some references before understanding:
1.An in vivo inflammatory loop potentiates KRAS blockade BioRxiv
Kristina A.M. Arendt, Giannoula Ntaliarda, Vasileios Armenis, Danai Kati, April 19 2020
2, RAS-inhibiting biologics identify and probe druggable pockets including an SII-a3 allosteric site.
BioRxiv 5th June 2020 Katarzyna Z Haza, View ORCID ProfileHeather et al (article which you may have read on Twitter)
We have identified two RAS-binding Affimer proteins, K3 and K6, that inhibit nucleotide exchange and downstream signalling pathways with distinct isoform and mutant profiles. Affimer K6 is the first biologic to bind in the SI/SII pocket, whilst Affimer K3 is the first non-covalent inhibitor of the SII region, revealing a novel RAS conformer with a large, druggable SII/a3 pocket. This work demonstrates the potential of using biologics with small interface surfaces to select novel druggable conformations in conjunction with pharmacophore identification for hard-to-drug proteins. KRAS GTPase activity and downstream signaling additionally prerequisites its integration into the cell membrane, which is facilitated by post-translational lipidation and membrane transport of KRAS by various enzymes such as farnesyltransferase (FT), geranylgeranytransferase (GGT), isoprenylcysteine carboxylmethyltransferase (ICMT), phosphodiesterased), and others (Stephen et al., 2014;Simanshu et al., 2017). To this end, therapeutic attempts to inhibit KRAS lipidation by targeting FT/GGT/ICMT were recently coupled by the development of PDEd blockers and of allosteric and covalent inhibitors of mutated KRASG12C (Winter-Vann et al., 2005; Zimmermann et al., 2013; Ostrem et al., 2013).
To make the EXPLANATION simple to understand IMO:
RAS mutations are common oncogenic (Cancer) drivers.These RAS mutations have been found in Pancreatic, Colonic and lung cancers . KRAS proto oncogene is holygrail of anticancer therapy .
It is importanat to note that until now, despite coordinated efforts anti-KRAS DRUG discovery is lagging behind other oncogene targets .
Now that K3 and K6 RAS binding affirmer proteins binding to druggable pockets have been identified to inhibit nucleotide exchange and thus down-stream mutations and cancer pathways . (This also involves complex enzymatic pathways FT, GGT and ITMT as mentioned in para1). Essentially Affirmers potentially offer what some anti-cancer drugs have been unable to do, but will need further studies on this application. IMO
Just Here- It seems like everyone is fed up and now taking a mick out of waiting situation which should ideally NOT be the case. Hold back guys . If you believe in fundamentals please wait .
From the last 10 funny posts my guess is they can't wait anymore.
Seethral - As you have been here in this Aims game for a while including placings Do you have any approx idea of how many shares are usually offered
-1. via primary bid.com and 2 via your broker ie HL ? what criteria are used to determine number of shares offered?? asa time in GDR was offered one third of the requested shares
Agree UPSIDE is Massive .
But is a waiting game till when?? Have to say news relay by Hemo has been very poor and untimely increasing the frustration for share holders like me. Hope they learn to convey this regularly
On another note , there is so much happening on other covid stocks including placing offers.